KSP-0243 / Kissei - LARVOL DELTA

An Early Phase 2 Clinical Study of KSP-0243 (clinicaltrials.gov) - P2 | N=108 | Completed | Sponsor: Kissei Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Oct 2024 | Trial primary completion date: Mar 2025 ➔ Oct 2024

Trial completion • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Phase IIa, randomized, double-blind, placebo-controlled, multicentre study of a once daily multiple oral administration of KSP-0243 in patients with mild-to-moderate ulcerative colitis (clinicaltrialsregister.eu) - P2 | N=30 | Completed | Sponsor: Kissei Pharmaceutical Co., Ltd.

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

An Early Phase 2 Clinical Study of KSP-0243 (clinicaltrials.gov) - P2 | N=100 | Active, not recruiting | Sponsor: Kissei Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

An Early Phase 2 Clinical Study of KSP-0243 (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Kissei Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

An Early Phase 2 Clinical Study of KSP-0243 (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: Kissei Pharmaceutical Co., Ltd.

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis